The introduction of @entity4149 kinase inhibitor (TKI) therapy has markedly reduced the use of allogeneic (allo) hematopoietic stem cell transplantation (HSCT), which is no longer standard practice in the first chronic phase in @entity1860 and is currently reserved after failure of TKI or in advanced phase of disease. We compared the outcome of @entity1860 @entity1 who received a first allo-HSCT in our center in both the pre-TKI era and the TKI era. The primary end point was to compare the 2 groups' @entity1349 ( @entity1349 ), @entity1778 ( @entity1778 ), cumulative incidence of nonrelapse mortality, and relapse incidence. The secondary end point was to underline in the TKI era the impact of the pretransplantation @entity41 ( @entity41 ) on the outcomes. A total of 69 @entity1 with Ph+ @entity1778 were included and their outcomes analyzed. For the purpose of this analysis, we defined 2 groups: group A (n  = 39) included @entity1 treated in the pre-TKI era, treated from January 1989 until December 2001, and group B (n  = 30) included @entity1 treated in the TKI era, treated from January 2002 until December 2013. Additional analysis was performed in group B for whom detailed TKIs and @entity41 data were collected. The study took place in our @entity5 center in the department of HSCT, Villejuif, France. The median follow-up duration for group A was 116.1 months (range, 1.1 to 240.1 months) and for group B was 8.3 months (range, 3.5 to 141.7 months). At 3  years, the @entity1778 and @entity1349 were higher in group B (respectively, 66% and 71%) than in group A (respectively, 63% and 57%) (P > .05). The @entity1778 and @entity1349 at 3 years of the pretransplantation @entity41 -negative (< 0.01%) @entity1 were significantly (P  < .05) higher (respectively, 83% and 94%) than the pretransplantation @entity41 -positive @entity1 (respectively, 43% and 46%). Our data, although statistically not significant, suggest better outcomes for Ph+ @entity1778 @entity1 undergoing allo-HSCT in the TKI era. Mostly TKI does not adversely affect the transplantation outcomes and can be used successfully as a bridge to allo-HSCT, especially in @entity1442 . In addition, we highlight the importance of obtaining deep pretransplantation @entity41 negativity.

Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia XXXX : 25 Years' Experience at Gustave Roussy Cancer Campus.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity41 :: ('MESH:D018365', 'Disease') :: ['MRD', 'minimal residual disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia-free survival', 'LFS', 'leukemia'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity1860 :: ('MESH:D015464', 'Disease') :: ['Philadelphia chromosome-positive (Ph+) leukemia', 'chronic myelogenous leukemia'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1778 :: (MESH:D007938,Disease) :: ['Chromosome-Positive Leukemia']
